Navigation Links
New Data Presented on Micardis (Telmisartan) Tablets in,Hypertensive Patients With Type 2 Diabetes

This condition should be corrected prior to administration of MICARDIS tablets, and treatment should start under close medical supervision.

The most common adverse events occurring with MICARDIS tablets monotherapy at a rate of 1% and greater than placebo, respectively, were: upper respiratory tract infection (URTI) (7%, 6%), back pain (3%, 1%), sinusitis (3%, 2%), diarrhea (3%, 2%), and pharyngitis (1%, 0%). Post-market adverse reactions include bradycardia, eosinophilia, thrombocytopenia, uric acid increase, abnormal hepatic function/liver disorder and renal impairment including acute renal failure, anemia and increased creatine phosphokinase.

About Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 137 affiliates in 47 countries and approximately 38,400 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2006, Boehringer Ingelheim posted net sales of US $13.3 billion (10.6 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.

    For more information, please visit http://us.boehringer-ingelheim.com.


    References


    (1) Burgess E et al. Efficacy of telmisartan compared with losartan in

        reducing proteinuria in hypertensive type 2 diabetic patients with

        overt nephropathy. Presented at the Annual Meeting of the European
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and Maintenance vs. Placebo
Post Your Comments:
(Date:8/3/2015)... 3, 2015 Discovery Laboratories, Inc. (Nasdaq: ... on developing aerosolized KL4 surfactant therapies for respiratory ... at 8:30 a.m. Eastern Time on Tuesday August 11, ... 2015 second quarter financial results along with providing ... press release announcing the second quarter 2015 financial ...
(Date:8/3/2015)... 3, 2015 AcelRx Pharmaceuticals, Inc. (Nasdaq: ... development and commercialization of innovative therapies for the treatment ... reported financial results for the three and six months ... , On July 23, 2015, the Committee for ... opinion for Zalviso™ for the management of acute moderate-to-severe ...
(Date:8/3/2015)... Diplomat Pharmacy, Inc. (NYSE: DPLO ), the nation,s largest ... June 30, 2015. All comparisons, unless otherwise noted, are to ... Quarter 2015 Highlights include: , Revenue of $808 ... Total prescriptions dispensed of 234,000, an increase of 19% ... EBITDA of $22.7 million, an increase of 287% or $16.8 ...
Breaking Medicine Technology:Discovery Labs to Hold Conference Call on Tuesday August 11, 2015 to Discuss Second Quarter 2015 Financial Results and Other Business Updates 2AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 2AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 3AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 4AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 5AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 6AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 7AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 8AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 9AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 10Diplomat Announces 2nd Quarter 2015 Financial Results 2Diplomat Announces 2nd Quarter 2015 Financial Results 3Diplomat Announces 2nd Quarter 2015 Financial Results 4Diplomat Announces 2nd Quarter 2015 Financial Results 5Diplomat Announces 2nd Quarter 2015 Financial Results 6Diplomat Announces 2nd Quarter 2015 Financial Results 7Diplomat Announces 2nd Quarter 2015 Financial Results 8Diplomat Announces 2nd Quarter 2015 Financial Results 9Diplomat Announces 2nd Quarter 2015 Financial Results 10Diplomat Announces 2nd Quarter 2015 Financial Results 11Diplomat Announces 2nd Quarter 2015 Financial Results 12Diplomat Announces 2nd Quarter 2015 Financial Results 13Diplomat Announces 2nd Quarter 2015 Financial Results 14Diplomat Announces 2nd Quarter 2015 Financial Results 15Diplomat Announces 2nd Quarter 2015 Financial Results 16Diplomat Announces 2nd Quarter 2015 Financial Results 17Diplomat Announces 2nd Quarter 2015 Financial Results 18
(Date:8/3/2015)... ... 03, 2015 , ... Catalent Pharma Solutions, the leading global ... health products, today welcomed the announcement by OPKO Health that the US Food ... new treatment for chronic kidney disease (CKD) and vitamin D insufficiency, which uses ...
(Date:8/3/2015)... Los Angeles, CA (PRWEB) , ... August 03, 2015 , ... ... emergency dental services to help patients in need. Most people know that general health ... hospital emergency. Unfortunately, a fewer amount of people know where to turn to during ...
(Date:8/3/2015)... ... 03, 2015 , ... Novatus, Inc. today launched the largest ... well as announced the date of its next major release. , Version 6.0 ... tasks as well as enhancements to the customer experience. Users now enjoy ...
(Date:8/3/2015)... Florida (PRWEB) , ... August 03, 2015 , ... ... for Physician Leadership ® and Navigant Center for Healthcare Research and Policy Analysis ... , Fifty-five percent of respondents said they agreed or strongly agreed that the ...
(Date:8/3/2015)... NJ (PRWEB) , ... August 03, 2015 , ... ... to announce the development of it’s new program “Designing Secure Healthcare Systems” ... architects, engineers and technology leaders from healthcare organizations with access to the tactics, ...
Breaking Medicine News(10 mins):Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:Novatus Unveils Milestone Software Release 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4
... genetic risk factor that increases the likelihood that youth will ... of involved and supportive parenting, according to a new University ... issue of the Journal of Consulting and Clinical Psychology ... over time to see how a genetic risk factor interacts ...
... 10 Primary Wave Media, one of the ... announced the creation of its new 1-800-HOSPICE marketing ... care market has become very competitive and these ... Wave,s 1-800-HOSPICE marketing package provides individual hospices with ...
... ZweigWhite,s just-released 2009 AEC Industry Outlook: Strategy and ... shake-up in the markets that firm leaders in the ... most promising. While health care still holds the top ... on project funding, three of last year,s top five ...
... nation, , , TUESDAY, Feb. 10 (HealthDay News) -- A North Carolina ... more than doubled in that state since the early 1990s -- ... country as a whole. , "We were actually surprised by ... medicine at the University of North Carolina and the study,s lead ...
... Sport Science and Management degree programme. The first of its ... produce professionals with relevant knowledge and pertinent skills for engagement ... at facilitating the growth of the sports and leisure industry ... Asia Pacific sports market are evident. According to a global ...
... Alice Jacobs, MD, FACC, FAHA, director of the Cardiac ... is the recipient of the Drake Award. The award ... annual conference in Bethel, Maine. , The Drake ... Eugene Drake, considered to be the first physician in ...
Cached Medicine News:Health News:Study: Genetic risk for substance use can be neutralized by good parenting 2Health News:Primary Wave Media Launches 1-800-HOSPICE 2Health News:New Study Reveals Shake-Up in the Most Promising AEC Markets for 2009 2Health News:Chronic Low Back Pain Is on the Rise 2Health News:Chronic Low Back Pain Is on the Rise 3Health News:Nanyang Technological University launches first-ever sports degree in Singapore 2Health News:Nanyang Technological University launches first-ever sports degree in Singapore 3Health News:Boston Medical Center cardiologist receives Drake Award 2
Short single-horn bridge for insertion of instruments...
Albarran double-horn bridge for use with sheaths from 20-25 Fr and designed for accurate articulation of flexible devices....
Designed for accurate articulation of flexible devices....
... ZeroTip basket features a "no tip" ... stone approximation., Flexible Design, ZeroTip baskets ... retrieval of calyceal stones, 2.4Fr Diameter ... 3.6Fr working channel, a 2.4Fr sheath ...
Medicine Products: